CQV Reports Revenue and Net Profit Growth in Q1 2026, Solid Financial Position

Q1 2026 revenue of KRW 15.77B (+7.28% YoY), operating profit KRW 3.02B, net profit KRW 2.41B (vs. KRW 2.03B YoY).
Debt ratio 24%, cash and equivalents KRW 11.23B, net debt ratio 5% indicating stable financial structure.
KRW 2B of the outstanding 3rd series convertible bonds (KRW 12B, conversion price KRW 4,035) were converted into common shares in April 2026.
Ongoing patent infringement lawsuit from Merck (KRW 200M) in first trial.
EcoVadis rating dropped from Gold (2025) to Silver (March 2026).
No share buyback, cancellation, or dividend announced for the quarter.